Mike A Laffan Selected Research

Mike A Laffan Research Topics

6	Hemorrhage 01/2021 - 04/2005
2	von Willebrand Diseases (von Willebrand's Disease) 04/2013 - 10/2009
1	COVID-19 11/2021
1	Pathologic Neovascularization 11/2021
1	Thrombosis (Thrombus) 01/2021
1	Liver Diseases (Liver Disease) 01/2020
1	Critical Illness (Critically Ill) 01/2020
1	Vascular Malformations 01/2019
1	Wounds and Injuries (Trauma) 01/2019
1	Angiodysplasia 09/2013
1	Vascular System Injuries 10/2012
1	Inflammation (Inflammations) 01/2011
1	Myocardial Infarction 06/2008
1	Pancreatitis 04/2005
1	Sepsis (Septicemia) 04/2005
1	Chronic Pancreatitis 04/2005
1	Infections 04/2005
1	Disseminated Intravascular Coagulation 04/2005

6	von Willebrand FactorIBA 01/2019 - 10/2009
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2021 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2019
2	Thrombin FDA Link 01/2020 - 01/2018
2	CoagulantsIBA 01/2020 - 10/2012
2	Hemostatics (Antihemorrhagics)IBA 01/2019 - 04/2005
1	CytokinesIBA 11/2021
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 11/2021
1	Interleukin-1 (Interleukin 1)IBA 11/2021
1	Fibrin Fibrinogen Degradation ProductsIBA 11/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2021
1	prothrombin complex concentrates (PPSB)IBA 01/2021
1	ThrombomodulinIBA 01/2021
1	FibrinIBA 01/2019
1	Becaplermin (PDGF-BB)FDA Link 01/2019
1	Pharmaceutical PreparationsIBA 01/2017
1	Carrier Proteins (Binding Protein)IBA 10/2012
1	Factor VIII (Coagulation Factor VIII)IBA 10/2012
1	Glycoproteins (Glycoprotein)IBA 01/2011
1	CollagenIBA 10/2009
1	Tranexamic Acid (AMCA)FDA Link 06/2008
1	recombinant FVIIa (rFVIIa)FDA Link 04/2005
1	Factor VIIa (Activated Factor VII)IBA 04/2005
1	Dacarbazine (DIC)FDA LinkGeneric 04/2005

1	Critical Care (Surgical Intensive Care) 01/2018
1	Therapeutics 09/2013